insulin glargine (Toujeo)

following an abbreviated submission

Insulin glargine (Toujeo®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of type 1 or type 2 diabetes mellitus in adults aged 18 years and above.

SMC restriction: Its use should be targeted on patients with Type I diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin.  In patients with type 2 diabetes it should be restricted to those who suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections.

It should be used in patients in whom treatment with an insulin analogue is appropriate. Insulin glargine 300 units/mL (Toujeo®) has similar efficacy but is not bioequivalent to insulin glargine 100 units/mL (Lantus®) and therefore not interchangeable without dose adjustment. At doses that provide comparable glycaemic control, Toujeo® is available at a similar cost to Lantus®.